AxoProtego Therapeutics

AxoProtego Therapeutics is a private biotechnology company developing neuroprotective small molecules for peripheral neuropathy and other neurologic conditions. Its lead program, EQ-6, is being advanced for prevention of chemotherapy-induced peripheral neuropathy, a common dose-limiting toxicity of cancer treatment. The company's pipeline is based on ethoxyquin and proprietary analogs licensed from Johns Hopkins University, with compounds designed to modulate HSP90-linked neurodegeneration pathways while preserving chemotherapy activity. Beyond oncology supportive care, AxoProtego has described follow-on opportunities in neurodegenerative and neuropathic disorders including multiple sclerosis, Parkinson's disease, and diabetic peripheral neuropathy. The company appears to remain in the preclinical stage and is headquartered in Glen Burnie, Maryland.